Shekher Bose: Asundexian’s Targeted Factor XIa Inhibition May Transform Secondary Stroke Prevention Strategies
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence’s post on LinkedIn, adding:
”Asundexian’s targeted Factor XIa inhibition offers potent antithrombotic protection with a differentiated safety profile (minimal impact on hemostasis), potentially transforming care for millions worldwide and could pave the way for broader, safer secondary stroke prevention strategies—if approved.”
Quoting Beyondsight Intelligence‘s post:
”Bayer’s Asundexian Cuts Stroke Risk by 26%, No increase in major bleeding in Phase 3
Bayer reported positive topline results from the Phase 3 OCEANIC-STROKE trial evaluating asundexian (50 mg), an investigational once-daily oral Factor XIa inhibitor.
Key Highlights:
• 26% reduction in recurrent stroke risk vs placebo
• Studied in patients with prior non-cardioembolic ischemic stroke or high-risk TIA
• Added on top of standard antiplatelet therapy
• No increase in ISTH major bleeding vs placebo
• Designed for effective thrombosis prevention with a wider safety margin
Why It Matters:
• Current antithrombotics often require a trade-off between efficacy and bleeding risk
• Factor XI inhibition is emerging as a next-generation anticoagulation strategy
• Could enable safer long-term secondary stroke prevention
Key Takeaway:
Asundexian’s Phase 3 results suggest meaningful stroke risk reduction without the usual bleeding penalty—potentially reshaping the future of antithrombotic therapy.
Follow our page for more such updates.
News Source Demonstrated a Substantial Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo”
Stay updated with Hemostasis Today.
-
Feb 6, 2026, 17:29Alexis Guédon: Cardiovascular Risk Profiles and Outcomes in Patients With Giant Cell Arteritis
-
Feb 6, 2026, 17:18William E.: Rho-Kinase Identified as a Novel Target in Post-COVID-19 Vascular Disease
-
Feb 6, 2026, 17:00Merry Mazmanian: Exploring the Development of Biobank Infrastructure in Armenia
-
Feb 6, 2026, 16:58Wolfgang Miesbach: A Hidden Platelet Activation State Bridging Thrombosis and Inflammation
-
Feb 6, 2026, 16:41Lester Leung on Launching a New Era in Preventing Silent Stroke and Dementia
-
Feb 6, 2026, 16:24Roseline d’Oiron on The Challenges of Pregnancy and Childbirth in Glanzmann Thrombasthenia at EAHAD 2026
-
Feb 6, 2026, 16:22Louise St Germain Bannon: ISTH Collaborates With EAHAD to Advance Care for People with Bleeding Disorders
-
Feb 6, 2026, 16:03Paula Loughnane: Honoured to Be Awarded Best SLAM Presentation at EAHAD 2026 AHP Day
-
Feb 6, 2026, 15:58Robert Hamilton: What Actually Makes Technology Stick at The Bedside